[Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
Sznajd
J
J
Malczewska-Malec
M
M
Idzior-Waluś
B
B
Iwanejko
J
J
Nowacki
G
G
D001053:Apolipoproteins / Q000097:blood; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D015248:Gemfibrozil; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000097:blood / Q000188:drug therapy*; D010421:Pentanoic Acids / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood; D014631:Valerates / Q000627:therapeutic use*
D001053:Apolipoproteins; D010421:Pentanoic Acids; D014280:Triglycerides; D014631:Valerates; D002784:Cholesterol; D015248:Gemfibrozil
Ocena skuteczności Gemfibrozilu w pierwotnych dyslipoproteinemiach. Czećć II: Zalezność wyników leczenia od postaci dyslipoproteinemii.